Valsartan and indapamide are both medications used to treat high blood pressure, but they are distinct compounds with different mechanisms of action and are often used in combination therapy [1]. The patent EP4295839A1 refers to a specific formulation or use related to these drugs.
What does patent EP4295839A1 cover?
Patent EP4295839A1 describes a tablet formulation containing valsartan and indapamide, along with specific excipients [1]. The patent claims the composition of this tablet, aiming to improve its stability and manufacturing process. It does not cover the individual active ingredients themselves but rather a specific pharmaceutical composition that combines them.
How do valsartan and indapamide work?
Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels, thus lowering blood pressure [2]. Indapamide is a thiazide-like diuretic that increases the excretion of sodium and chloride, leading to reduced fluid volume and lower blood pressure [3]. Their combined effect can be more potent in managing hypertension than either drug alone.
Are valsartan and indapamide available as a combination product?
Yes, fixed-dose combination products containing valsartan and indapamide are available and prescribed for patients with hypertension [4]. These combinations offer the convenience of a single pill for patients requiring both medications.
What is the therapeutic benefit of combining valsartan and indapamide?
The combination of valsartan and indapamide provides a dual mechanism of action for blood pressure control. ARBs like valsartan are effective in reducing cardiovascular events, while diuretics like indapamide also contribute to blood pressure reduction and can help mitigate potential side effects like fluid retention that might occur with ARB monotherapy in some individuals [3][4].
What is the status of patent EP4295839A1?
Patent EP4295839A1 was published and is currently active. The term of a patent typically extends for 20 years from its filing date, though this can be affected by various factors including supplementary protection certificates (SPCs) in certain regions [5]. Information regarding the specific expiry date of this patent would require a detailed search of patent databases.
Can generic versions of valsartan and indapamide combinations be produced?
Generic versions of valsartan and indapamide combination products can be produced after the relevant patents expire and regulatory approval is obtained. The existence of patent EP4295839A1, which covers a specific formulation, means that generic manufacturers must ensure their products do not infringe this patent until it expires.
What other patents might cover valsartan and indapamide products?
In addition to formulation patents like EP4295839A1, there are likely to be patents covering the synthesis of valsartan and indapamide, as well as patents on other specific combination formulations or therapeutic uses. The intellectual property landscape for pharmaceutical products is often complex, involving multiple layers of patent protection.
Sources:
1. EP4295839A1, https://worldwide.espacenet.com/patent/search/family/057996591/publication/EP4295839A1?q=ep4295839a1
2. Valsartan, National Library of Medicine, https://pubchem.ncbi.nlm.nih.gov/compound/Valsartan
3. Indapamide, National Library of Medicine, https://pubchem.ncbi.nlm.nih.gov/compound/Indapamide
4. Combination Products, U.S. Food & Drug Administration, https://www.fda.gov/drugs/drug-approvals-and-databases/combination-products
5. Patent duration, European Patent Office, https://www.epo.org/about-us/office/reports-statistics/glossary/patent-duration.html